Technical report (Original)
The advent of high-throughput microarrays has shifted a paradigm from hypothesis-driven research to data-driven discovery [1] . Instead of setting up hypotheses and testing them one by one, potential hypotheses are mined from genome-wide data collected all at once. Recently, Gene Expression Omnibus (GEO) maintains data from over 10,000 experiments, and this number is increasing [2] [3] [4] [5] . A modern microarray is made up of >50,000 probes. Consequently, a plethora of genome-wide data have been produced and archived for re-analysis. The data collected by an investigator may be re-analyzed by another investigator. However, as it is done from a different point of view, it may yield other important discovery.
Another paradigm shift has taken place with respect to the role of bioinformatics. Bioinformatics has long been recognized as part of data analysis. Bioinformaticians are normally not the principal investigators who come up with the questions asked in primary medical discovery. However, Butte [6] has stimulated bioinformaticians to ask questions that no other scientists can ask or answer. He pointed out four reasons to enable bioinformaticians to be questioners. One of his reasons was "the intersection of data across multiple experiments".
The objective of this study is to explain how to find answers using software, called CU-DREAM. The CU-DREAM stands for connection up-and downregulation expression analysis of microarrays. It allows researchers to explore diseases, biological processes, and related mechanisms that alter genome-wide gene expression patterns and identify regulators and regulated genes. In the study, we devised CU-DREAM to compare the results of two independent microarray experiments. It was demonstrated that CU-DREAM could perform a comprehensive analysis of expression array databases to determine if there is a connection between the test variables of two expression microarray experiments. Common test variables including diseases, biological processes, environmental factors, and experimental conditions such as siRNA, immunoprecipitation, and genes, were studied. 
Methods

CU
Results
Five showcases were selected to demonstrate the functionality of CU-DREAM. All datasets used in the showcases are listed in Table 1 . These can be downloaded from GEO. The parameter setting for each showcase, including experimental and control groups, is available at project homepage. The first three datasets are from studies of cancer, and the last two are from studies of RNA interference (RNAi).
Showcase 1: CU-DREAM identified genes that were up-and down-regulated.
The experimental group was cervical cancer cells, and the control group was normal cells. CU-DREAM performs a t-test for each probe. A partial result is shown in Table 2 . A gene is up-regulated if "Mean1" (experimental group) is greater than "Mean2" (control group). Otherwise, the gene is down-regulated. The statistical significance is determined using a p-value threshold. This dataset included 54,675 probes. Note that Table 2 has been formatted for use in this paper; the actual CU-DREAM outputs are Excel files. Showcase 2: CU-DREAM validated significantly regulated genes.
We compared two cervical cancer expression libraries, GSE6791 and GSE7803, to identify genes that were up-and down-regulated in both libraries. Table 3 shows the up-up and down-down intersections between these two studies of cervical cancer. Each entry in the contingency table is the number of genes. The significant p-values and odds ratios >1 indicate the strong association between the two independent studies. More specifically, the genes that were up-regulated in one study were also upregulated in another study. This result confirmed that the two studies involved a common gene regulation mechanism. Importantly, microarrays include both unique probes (having one corresponding gene) and homology probes (having multiple corresponding genes). In addition, a gene may have multiple corresponding probes. Therefore, counting the number of genes is not straightforward. CU-DREAM uses a simple count algorithm. This algorithm is documented in the user manual. CU-DREAM also outputs gene symbols in sets A, B, C, and D.
Showcase 3: CU-DREAM determined if two different diseases had a similar effect on gene regulation.
We compared lung cancer (GSE5816) and cervical cancer (GSE6791). This showcase deliberately used different tissues, the lungs, and the cervix, as shown in Tables 4. The result is similar to that of the previous showcase, but the p-values and odds ratios are less significant for this showcase. This is expected because different types of cancer tissues are less likely to share the same regulated genes and underlying mechanisms than two samples of the same type of cancer. 
Showcase 4: CU-DREAM identified isoformchanged genes.
Many genes have more than one isoform as the result of alternative splicing or the use of alternative promoters. CU-DREAM helps identify multi-isoform genes. Expression microarrays detect the majority of genes using multiple corresponding probes. If a gene shows as both up-and down-regulated, then the different isoforms of the gene may be differentially regulated. Here, we determined if there were isoform changes in lung cancer by comparing up-and downregulated genes in lung cancer cells (GSE5816). We can intersect the up-and down-regulated genes identified in a single study, as shown in Table 5 . A gene can be counted as both up-and down-regulated because there are multiple corresponding probes. Some probes may show up-regulation and some probes may show down-regulation. The intersection of up and down could reveal "isoforms" that exhibit differential expression between the experimental and control groups. We found that there might be isoform changes for at least 23 genes.
Showcase 5: CU-DREAM determined if cells shared gene regulation mechanisms.
We present the result of two different experiments that experimentally depleted different proteins. However, these proteins are known to form a complex and consequently down-regulate a common set of genes. We compared cells that had lower levels of Dicer and Ago2: HEK293 cells from GSE4246. Dicer and Ago2 form the RISC complex, which generates small RNA to limit mRNA levels at the posttranscriptional level (RNAi) or which activates transcriptional processes (RNAa) [12] . There are four Argonaute proteins, Ago1, Ago2, Ago3 and Ago4. A low Dicer concentration will limit the amount of RISC derived from Dicer and all Argonautes. However, a low Ago2 concentration will limit only the amount of RISC derived from Dicer and Ago2. Therefore, lowering the level of Dicer should reveal up-and down-regulated genes that are also up-and downregulated by Ago2 depletion. Table 6 shows the CU-DREAM results for Dicer and Ago2. Both up vs. up and down vs. down intersections had significant odds ratios >1. Obviously, the up-up genes should be regulated by RNAi, but the down-down genes suggest a possibility of another underlying mechanism, is complementary to RNAi. This process is known as RNAa. We analyzed the mRNA expression of cells that were depleted of Dicer mRNA, but these cells were different cell types, cervical cancer (HeLa), cells and embryonic kidney (HEK293) from GSE13638 and GSE4246, respectively. Table 7 shows that the intersection of different tissues is plausible, but the p-values are less significant than those for intersections of the same tissue.
Discussion
Expression microarrays yield useful information. The most common information to extract is the identity of the up-and down-regulated genes. We designed CU-DREAM to be a tool not only to identify regulated genes but also to compare different experiments. A comparison within the same experiment between upand down-regulated genes can be used to identify genes with several isoforms that are differentially regulated under the experimental conditions. For example, at least 23 isoforms were differentially regulated when cells were transformed to become lung cancer.
The main objective of CU-DREAM is to compare data from two different experiments. There are several main benefits of this approach. First, CU-DREAM helps researchers to validate regulated genes under the same conditions, as demonstrated in the showcase comparing two expression arrays for cervical cancer cells. Second, CU-DREAM helps to differentiate biological conditions. For example, there are numerous cancer cell types, but they may be very similar at the molecular level. If this is the case, the odds ratio should be >1, as demonstrated by the comparison of cervical and lung cancers; a higher odds ratio was obtained when different cervical cancers from different GSEs were compared. This result suggests that the gene regulation is similar among many different types of cancers and cells of the same cancer type share more regulated genes. Therefore, a high CU-DREAM odds ratio between regulated genes in the same direction may group two pathological lesions together. Recently, it has been shown that ovarian clear-cell and ovarian endometrioid carcinomas frequently contain a somatic mutation in the same gene [13] . We analyzed these two carcinomas with CU-DREAM and found odds ratios of 22.7 and 36.8 for the up-up and down-down intersections, respectively (data not shown). Note that the odds ratio has a symmetry property. The group (row) and event (column) can be used interchangeably. Significant odds ratios above one indicate the likelihood that the two experiments share the same gene regulation pathways. On the contrary, odds ratios below one indicate that the event of interest ("up" or "down") is more likely to happen in the control group for the prior t-test or that the up-stream regulators acted significantly in the opposite direction.
CU-DREAM leads to a better understanding of human biology and of the pathogenesis of diseases by identifying connections between two different 
